BEONE MEDICINES LTD. (BEIGF) Return on equity 2016–2025
BEONE MEDICINES LTD. (BEIGF) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
6.6%FY2025 · since FY2016: -33.8% → 6.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 6.6% | +25.9 pp |
| FY2024 | -19.4% | +5.6 pp |
| FY2023 | -24.9% | +20.8 pp |
| FY2022 | -45.7% | -21.9 pp |
| FY2021 | -23.8% | +18.2 pp |
| FY2020 | -42.0% | +56.6 pp |
| FY2019 | -98.6% | -59.8 pp |
| FY2018 | -38.7% | -24.8 pp |
| FY2017 | -13.9% | +19.9 pp |
| FY2016 | -33.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More BEIGF financial trends
BEIGF RevenueBEIGF Net incomeBEIGF Net marginBEIGF Gross profitBEIGF Gross marginBEIGF Operating incomeBEIGF Operating marginBEIGF Operating cash flowBEIGF Free cash flowBEIGF Capital expendituresBEIGF Stock buybacksBEIGF Dividends paidBEIGF Total assetsBEIGF Total liabilitiesBEIGF Shareholders’ equityBEIGF overview →